Taro rejects Sun Pharma offer

Thursday, July 19, 2012 02:25 PM

The special committee of the board of directors of Taro Pharmaceutical Industries unanimously rejected the Oct. 18, 2011, unsolicited, non-binding offer from Sun Pharmaceutical Industries—to purchase all of the issued and outstanding shares of Taro not currently held by Sun Pharma for $24.50 per share—as inadequate and not in the best interests of Taro's minority shareholders.

The special committee reached its conclusion after careful consideration, including a thorough review of Taro's business and prospects with its independent financial advisor legal counsel.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

June 17

New CISCRP study finds patient perceptions of trial participation safety, motives greatly improved

PwC: Volume and value of pharma, diagnostics deals soar in first quarter, as CRO sector waits on sidelines

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

June

Operating environment spurs out-of-the-box ideas
High cost, low success rates drive some sponsors to new monitoring, protocol design, patient-centric initiatives

Private equity interest in CROs could lead to more IPOs
Now flush with cash, many PE investors readying to cash out

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

May

INC Research, PPD, inVentiv named top CROs
Yet most CROs slipping in ability to manage site relationships

R&D cuts by sponsors spur more collaboration, innovation
New strategies share pipeline activity costs

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs